文献速递心境障碍

氯胺酮急性给药纠正重性抑郁障碍患者异常炎症骨标志物

Acute ketamine administration corrects abnormal inflammatory bone markers in major depressive disorder.
PubMed 文献 · Mol Psychiatry · 2017-05-30

MDD患者基线OPG/RANKL比值和血浆骨桥蛋白(OPN)水平显著降低;氯胺酮显著升高OPG/RANKL比值和OPN水平,并显著降低RANKL水平,而健康对照的骨标志物水平保持不变。结论提示OPG-RANK-RANKL系统和OPN系统在MDD相关骨异常中起重要作用,氯胺酮除抗抑郁外对抑郁疾病的主要医学并发症也有益。

要点

  • MDD患者基线OPG/RANKL比值和血浆OPN水平显著降低。
  • 氯胺酮显著升高OPG/RANKL比值和OPN水平,并显著降低RANKL水平。
  • 健康对照的骨标志物水平在氯胺酮后保持不变。

核心结论

  • OPG-RANK-RANKL系统和OPN系统在MDD相关的严重骨异常中起重要作用。
  • 氯胺酮除抗抑郁作用外,对抑郁疾病的主要医学并发症也有益。

研究设计与样本

  • 测量外周骨标志物水平及其对静脉氯胺酮输注的响应,时间点为基线、输注后230分钟、第1天和第3天。

主要发现

  • MDD患者基线OPG/RANKL比值和血浆OPN水平显著降低。
  • 氯胺酮显著升高OPG/RANKL比值和血浆OPN水平,并显著降低RANKL水平。
  • 健康对照的骨标志物水平保持不变。

关键数值与推荐

  • MDD患者基线OPG/RANKL比值和血浆OPN水平显著降低。
  • 氯胺酮显著升高OPG/RANKL比值和血浆OPN水平,并显著降低RANKL水平。

临床怎么用

  • 提示临床关注MDD患者的骨代谢异常,氯胺酮可能对骨标志物有矫正作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with major depressive disorder (MDD) have clinically relevant, significant decreases in bone mineral density (BMD). We sought to determine if predictive markers of bone inflammation-the osteoprotegerin (OPG)-RANK-RANKL system or osteopontin (OPN)-play a role in the bone abnormalities associated with MDD and, if so, whether ketamine treatment corrected the abnormalities. The OPG-RANK-RANKL system plays the principal role in determining the balance between bone resorption and bone formation. RANKL is the osteoclast differentiating factor and diminishes BMD. OPG is a decoy receptor for RANKL, thereby increasing BMD. OPN is the bone glue that acts as a scaffold between bone tissues matrix composition to bind them together and is an important component of bone strength and fracture resistance. Twenty-eight medication-free inpatients with treatment-resistant MDD and 16 healthy controls (HCs) participated in the study. Peripheral bone marker levels and their responses to IV ketamine infusion in MDD patients and HCs were measured at four time points: at baseline, and post-infusion at 230 min, Day 1, and Day 3. Patients with MDD had significant decreases in baseline OPG/RANKL ratio and in plasma OPN levels. Ketamine significantly increased both the OPG/RANKL ratio and plasma OPN levels, and significantly decreased RANKL levels. Bone marker levels in HCs remained unaltered. We conclude that the OPG-RANK-RANKL system and the OPN system play important roles in the serious bone abnormalities associated with MDD. These data suggest that, in addition to its antidepressant effects, ketamine also has a salutary effect on a major medical complication of depressive illness.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Kadriu B, Gold PW, Luckenbaugh DA, et al. Acute ketamine administration corrects abnormal inflammatory bone markers in major depressive disorder. Mol Psychiatry. 2017. PMID: 28555075. doi:10.1038/mp.2017.109

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。